Clinical Trial Search

Primary: Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 6 — 2.5; 5.0 Percentage of Participants — p=0.021

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.5; 96.2; 97.3 Percentage of participants…

Primary: Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers — 1801.23; 1722.83; 1778.48…

Primary: Percentage of Participants With Adverse Events (AEs) — 30.2; 39.0; 30.0 percentage of participants

Primary: Change From Baseline to Week 12, Expressed as a Ratio, in Number of Airway Submucosal Eosinophils — 1.29; 1.07 Ratio — p=0.3862

Primary: Change From Baseline (Visit 2) of the Local PSI of the Blue Light Treated Area (Group 30) as Compared to the VitaminD Treated Area (Control) at End of Treatment (Week…

Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33

Primary: Change in Metabolic Rate — 7.6; 18 percentage of increase in REM and SEE

Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086

Primary: Number of Participants With Complications; One of the Following Events — 0; 0 Participants

Primary: Distance Binocular Visual Acuity — -0.056; -0.075 logMAR

Primary: Number of Patients Alive and Progression Free After 6 Months — 1 Participants

Primary: Success Rates of the Procedure — 37; 38; 39; 30 Participants — p=0.007

Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 909; 954; 269 Number of events

Primary: Patient Quality of Life — 79.51; 76.91; 82.70; 78.85 units on a scale